Pharma Exclusives Pressreleases
Tufts Center Study Shows Significant Time Savings in Delivering Therapies to Patients with Thermo Fisher Scientific’s Accelerator™ Drug Development 360° CDMO and CRO Solutions
Monday, June 16, 2025Thermo Fisher Scientific Inc the world leader in serving science today announced the findings of new research by the Tufts Center for the Study of Drug Development CSDD demonstrating the benefits of the companys Accelerator
Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at Increased Risk for RSV Disease
Friday, June 13, 2025Moderna Inctoday announced that the US Food and Drug Administration FDA has approved mRESVIA mRNA the Companys respiratory syncytial virus RSV vaccine for the prevention
AstraZeneca enters strategic collaboration with CSPC Pharmaceuticals focused on AI-enabled research
Friday, June 13, 2025AstraZeneca has entered a strategic research collaboration with Shijiazhuang Citybased CSPC Pharmaceuticals Group Limited Working together on high priority targets the collaboration aims to advance
Biomea Fusion Presents Updated Preliminary Clinical Data for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia at EHA 2025
Friday, June 13, 2025Biomea Fusion Inc a clinicalstage diabetes and obesity medicines company today announced updated preliminary clinical data from the ongoing Phase I COVALENT trial of BMF in adults
Biogen Highlights the Potential of Felzartamab for a Range of Immune-Mediated Diseases Including Three Phase 3 Programs in Rare Kidney Diseases
Thursday, June 12, 2025Biogen Incwill host a virtual investor seminar today at am ET focused on the potential of the investigational drug felzartamab in rare kidney diseases and the potential to target CD for a range of immunemediated diseases
U.S. FDA Approves Expanded Indication for AbbVie's MAVYRET® (Glecaprevir/Pibrentasvir) as First and Only Treatment for People with Acute Hepatitis C Virus
Thursday, June 12, 2025AbbVietoday announced that the US Food and Drug Administration FDA approved a label expansion for MAVYRET glecaprevirpibrentasvir an oral pangenotypic direct acting antiviral DAA therapy
U.S. FDA Approves Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Born During or Entering
Tuesday, June 10, 2025Merckknown as MSD outside of the United States and Canada today announced the US Food and Drug Administration FDA has approved ENFLONSIA clesrovimabcfor for the prevention of respiratory syncytial virus
U.S. FDA Approves Merck’s ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants
Tuesday, June 10, 2025Merckknown as MSD outside of the United States and Canada today announced the US Food and Drug Administration FDA has approved ENFLONSIA clesrovimabcfor for the prevention of respiratory syncytial virus RSV
Merck Announces Positive Topline Results From the First Two Phase 3 CORALreef Trials Evaluating Enlicitide Decanoate for the Treatment of Adults With Hyperlipidemia
Monday, June 09, 2025Merckknown as MSD outside of the United States and Canada today announced positive topline results from the first two of three Phase clinical trials evaluating the safety and efficacy of enlicitide decanoate
Celularity Announces Publication Advancing Ocular Surface Reconstruction with Tri-Layer Amniotic Membrane Technology
Tuesday, June 03, 2025Celularity Inc a regenerative and cellular medicine company today announced its research published in the May issue of the peerreviewed journal Regenerative Engineering and Translational Medicine a leading openaccess journal publishing cuttingedge...
